Navigation Links
Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
Date:4/3/2009

Kingchem to Act as Agent to Find Partner to Co-Develop Company's Chinese Patented Skeletal Muscle Relaxant for North American Markets

LAS VEGAS, April 3 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma") (the "Company") is pleased to announce that it has signed an export agreement with Kingchem, an international marketing organization headquartered in New Jersey that specializes in custom manufacturing and sourcing of pharmaceuticals. Under the two-year agreement, Kingchem will act as an agent to find a U.S. pharmaceutical company to co-develop Sinobiopharma's Chinese patented new version of Cisatracurim besylate, a non-depolarizing pre-surgical skeletal muscle relaxant, for use in North America. Kingchem will also source buyers in North America and facilitate the export process.

Marketed under the Kutai trademark in China, the Company's formulation of Cisatracurim besylate is the world's first that can be stored at room temperature; competitors' versions must be kept at 2 to 8 degrees C. Compared to other neuromuscular blocking agents, Kutai, which is administered intravenously, is immediate in onset and longer in duration. Kutai captured an estimated 80 percent of the Chinese market within 14 months of its launch in China.

Kingchem is a well-established, respected supplier to the pharmaceutical, nutritional and fine chemical industries in the United States and Europe. With more than a decade of service, Kingchem has been recognized by its customers as a quality and reliable supplier.

"We believe this agreement is a first step in expanding the international marketing of Kutai to help generate increased sales revenues," said Sinobiopharma Vice President, Xuejun Chen.

About Kingchem LLC

Kingchem LLC acts as a third party manufacturer's agent, representing a group of first class manufacturers in China and in other parts of the world in the pharmaceutical, fine and specialty chemical, and nutritional and health food industries.

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD-LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward-looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
2. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
3. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
4. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
5. Monsanto Company Signs Share Subscription Agreement With Devgen
6. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
7. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
8. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
9. Assay Designs(TM) Announces Additions to the Leadership Team
10. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
11. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... replacement at the Caribbean Neurosciences Symposium (CANS) annual meeting in Montego Bay, Jamaica ... technology and host a hands-on workshop for surgeons to experience the simplicity of ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... endeavors to bring to market a pioneering medical device for the treatment of ... an engagement contract with Emergo, a global regulatory consultancy that helps companies like ...
(Date:1/21/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, today presented data from two clinical ... 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers ... In a Phase Ib/II study of napabucasin ... cancer stemness pathways by targeting STAT3 – colorectal cancer ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Health Organization, cancer is one of leading causes of ... in 2012. Although the number of cancer related deaths ... since 1990. Rising in incidence rate of various cancers ... According to a research report by Global Market Insights, ...
Breaking Biology Technology:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):